Senti Biosciences, Inc.

Senti Biosciences, Inc. (Nasdaq: SNTI) is a clinical-stage synthetic biology company developing gene circuit-engineered cell and gene therapies for oncology and other serious diseases. The company entered the public markets through a de-SPAC transaction with Dynamics Special Purpose Corp., a blank-check vehicle that completed its initial public offering in 2021 and was sponsored by Dynamics Special Purpose Holdings LLC. The amended quarterly report filed with the SEC on December 10, 2021, bearing accession number 0001193125-21-353981, covers activity during the pre-merger period in the life sciences and biotechnology sector. The combined entity subsequently began trading on Nasdaq under the ticker SNTI. Investors seeking full filing history, deal analytics, and real-time SPAC data for SNTI can sign up at SpacDesk.